News Releases

News Releases

Webcast ImageWebcast
Pacira Pharmaceuticals, Inc. at the BMO Capital Markets: Prescriptions for Success Healthcare Conference  (Replay)
12/14/17 at 11:30 a.m. ET
Pacira Pharmaceuticals, Inc. at the BMO Capital Markets: Prescriptions for Success Healthcare Conference
Thursday, December 14, 2017 11:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Illinois Surgical Quality Improvement Collaborative and Pacira Pharmaceuticals, Inc. Announce Collaboration to Minimize Opioid Exposure for Postsurgical Patients
12/14/17
Pacira Pharmaceuticals to Present at the 2017 BMO Capital Markets Prescriptions for Success Healthcare Conference
12/08/17
Pacira Announces Promotions of Scott Braunstein, MD, to Chief Operating Officer and Richard Scranton, MD, to Chief Scientific Officer
12/07/17
Cancer Treatment Centers of America® Teams with Pacira Pharmaceuticals, Inc. on Innovative Collaboration to Educate Physicians and Patients about Responsible Opioid Use
11/29/17
Pacira Announces FDA Advisory Committee Meeting to Review sNDA for EXPAREL® as a Nerve Block for Regional Analgesia
11/14/17
Pacira Pharmaceuticals to Present at Two November Healthcare Conferences
11/09/17
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2017 Financial Results
11/08/17
Pacira Pharmaceuticals Announces Timing for Third Quarter 2017 Financial Results Webcast and Conference Call
10/31/17
Pacira Pharmaceuticals and TELA Bio Announce Equity Agreement
10/25/17
Pacira Pharmaceuticals Announces FDA Acceptance of sNDA for EXPAREL as a Nerve Block to Produce Regional Analgesia
10/18/17
Pacira Pharmaceuticals CEO to Testify at White House Opioid Crisis Commission Meeting
09/27/17
New Research: Overprescribing of Postsurgical Opioids Poses a Serious Threat to Patients and their Communities; Women Undergoing Surgery are at Greatest Risk
09/26/17
Pacira Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
09/20/17
Pacira Pharmaceuticals, Aetna, and the American Association of Oral and Maxillofacial Surgeons Join Together in a Program to Reduce Opioid Exposure for Patients Undergoing Wisdom Tooth Extraction
09/13/17
Pacira Pharmaceuticals Announces Multiple EXPAREL Data Presentations at the Upcoming New York School of Regional Anesthesia Annual Fall Symposium
09/06/17
Pacira Pharmaceuticals to Present at the 2017 H.C. Wainwright 19th Annual Global Investment Conference
09/05/17
Pacira Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference
08/31/17
Pacira Pharmaceuticals to Present at the 2017 Wedbush Pacgrow Healthcare Conference
08/09/17
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results
08/02/17
Pacira Announces Publication of Phase 4 Study of EXPAREL in Patients Undergoing Total Knee Replacement in The Journal of Arthroplasty
07/26/17
Pacira Pharmaceuticals Announces Timing for Second Quarter 2017 Financial Results Webcast and Conference Call
07/25/17
Pacira Announces Topline Phase 3 Results for EXPAREL® as a Single-dose Nerve Block
07/25/17
Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors
06/15/17
Pacira Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
06/14/17
Pacira Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
06/01/17
Pacira Pharmaceuticals Announces Resignation of James Scibetta
05/23/17
Pacira Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
05/10/17
Pacira Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results
05/04/17
New Research Shows Vast Majority of Oral Surgery Patients Would Choose Non-opioid Medication to Treat Postsurgical Pain if Given the Option
05/03/17
Pacira Pharmaceuticals Announces Timing for First Quarter 2017 Financial Results Webcast and Conference Call
04/27/17
Pacira Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference
04/03/17
Trinity Health and Pacira Pharmaceuticals Announce Collaboration to Decrease Opioid Use Nationwide
03/16/17
Phase 4 Study Shows EXPAREL® Versus an Active Comparator Significantly Reduces Opioid Consumption and Postsurgical Pain in Patients Undergoing Total Knee Arthroplasty
03/14/17
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
03/13/17
Pacira Pharmaceuticals Announces Pricing of $300 Million Aggregate Principal Amount of 2.375% Convertible Senior Notes due 2022
03/07/17
Pacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate Principal Amount of Convertible Senior Notes
03/06/17
Pacira Pharmaceuticals Reports 2016 Financial Results and Provides Business Update
03/01/17
Pacira Pharmaceuticals Announces Timing for 2016 Financial Results Webcast and Conference Call
02/16/17
Pacira Pharmaceuticals, Inc. to Present at the 2017 RBC Capital Markets’ Healthcare Conference
02/15/17
Pacira Pharmaceuticals Announces Collaboration with DePuy Synthes to Support Promotion, Education and Training of EXPAREL® in Orthopedics
01/25/17
Pacira Pharmaceuticals Reports Preliminary 2016 Revenues of $276.4 Million
01/06/17
Pacira Pharmaceuticals, Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference
01/03/17
Pacira Pharmaceuticals and GeneAlign Announce Partnership to Develop Low-Opioid Pain Management Protocols for Postsurgical Patients at High Risk of Addiction
11/29/16
American College of Surgeons Launches Education Program on Opioids and Surgery: Use, Abuse, and Alternatives
11/22/16
Pacira Pharmaceuticals Unveils Virtual Reality Training Simulation to Enhance Administration Technique Education for EXPAREL® in Total Knee Replacement Surgery
11/11/16
Correction: Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in November
11/10/16
Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in November
11/10/16
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results
11/02/16
Pacira Pharmaceuticals Continues to Build Out Robust Commercial Leadership Team
10/20/16
Pacira Pharmaceuticals Announces Timing for Third Quarter 2016 Financial Results Webcast and Conference Call
10/17/16
Pacira Pharmaceuticals Announces Official Launch of EXPAREL to the Oral Surgeon Community to Treat Pain Following Oral and Maxillofacial Procedures
09/21/16
Pacira Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
09/01/16
Pacira Pharmaceuticals, Inc. to Present at the 2016 Wedbush PacGrow Healthcare Conference
08/09/16
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results
08/04/16
New Research: Opioid Addiction and Dependence After Surgery is Significantly Higher than Previously Known
08/01/16
Pacira Pharmaceuticals Announces Timing for Second Quarter 2016 Financial Results Webcast and Conference Call
07/15/16
Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2016 Healthcare Conference
05/31/16
Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
05/03/16
Pacira Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results
05/02/16
Pacira Pharmaceuticals Appoints Charles A. Reinhart III as Chief Financial Officer
04/19/16
Pacira Pharmaceuticals Announces Timing for First Quarter 2016 Financial Results Webcast and Conference Call
04/14/16
Pacira Pharmaceuticals Appoints Robert Weiland as Chief Commercial Officer
04/05/16
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
03/08/16
New Analysis Shows Use of EXPAREL Reduces Length of Hospital Stay and Improves Discharge Status Compared to Standard Analgesic Modality in Total Knee Arthroplasty
03/01/16
Pacira Pharmaceuticals, Inc. Reports 2015 Financial Results
02/25/16
Pacira Pharmaceuticals Announces Timing for 2015 Financial Results Webcast and Conference Call
02/11/16
Pacira Pharmaceuticals Reports Estimated Full-Year 2015 Total Revenue of $249.0 Million
01/07/16
Pacira Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference
12/28/15
Pacira Pharmaceuticals Announces Favorable Resolution With U.S. Food and Drug Administration, Which Reaffirms the Broad Indication for EXPAREL®
12/15/15
Pacira Pharmaceuticals, Inc. to Present at the 27th Annual Piper Jaffray Healthcare Conference
11/24/15
New Survey Sheds Light on Prescription Drug Use Among Women After Surgery in the United States
11/17/15
Pacira Pharmaceuticals, Inc. to Present at the Jefferies Autumn 2015 Global Healthcare Conference
11/11/15
New Study Finds Decreased Opioid Use, Hospital Stay and Readmission Rates With EXPAREL Following Knee Replacement Surgery
11/06/15
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial Results
10/27/15
Pacira Pharmaceuticals Announces the Promotion of James S. Scibetta to President
10/20/15
Pacira Pharmaceuticals Announces Timing for Third Quarter 2015 Financial Results Webcast and Conference Call
10/13/15
Pacira Pharmaceuticals Seeks Court Injunction to Defend its Rights to Share Information about EXPAREL® Consistent with its FDA-Approved Indication
09/08/15
Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, as Senior Vice President and Chief Medical Officer
08/19/15
Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in August
08/03/15
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results
07/30/15
Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results for Controlling Postsurgical Pain in Dogs
07/15/15
Pacira Pharmaceuticals Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call
07/14/15
Pacira Pharmaceuticals Appoints Scott Braunstein, MD, to Oversee Strategy and Corporate Development
07/14/15
Pacira Pharmaceuticals Announces Completion of End-of-Review Process with FDA Regarding EXPAREL sNDA for Nerve Block
05/28/15
Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in June
05/20/15
Pacira Announces New Data Supporting Clinical and Pharmacoeconomic Utility of EXPAREL in Patients Undergoing Various Surgical Procedures
05/19/15
Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
05/07/15
Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenues of $56.0 Million and First Quarter 2015 Financial Results
04/30/15
Pacira Receives Subpoena from the U.S. Department of Justice
04/16/15
Pacira Pharmaceuticals Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call
04/13/15
Pacira Announces New Data on Health Economic Benefits of EXPAREL for Postsurgical Pain Control Following Total Knee Replacement Surgery
04/10/15
Pacira Announces Data Reinforcing Benefits of EXPAREL® for Postsurgical Pain Control Following Total Hip and Knee Replacement Surgery
03/26/15
New Data Demonstrate Reduced Opioid Requirements Following Use of EXPAREL in Hysterectomy and Mastectomy Procedures
03/23/15
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
03/04/15
Pacira Receives Complete Response Letter from FDA for sNDA Seeking Approval of EXPAREL® Use in Nerve Block to Provide Postsurgical Analgesia
03/02/15
Pacira Pharmaceuticals, Inc. Reports 2014 Financial Results
02/24/15
Pacira Pharmaceuticals, Inc. Announces Resolution of Warning Letter with FDA’s Office of Prescription Drug Promotion
02/11/15
Pacira Pharmaceuticals Announces Timing for 2014 Financial Results Webcast and Conference Call
02/10/15
Pacira Pharmaceuticals, Inc. to Host Analyst & Investor Day on Jan. 22 in New York
01/08/15
Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue of $61.8 Million and Estimated Full-Year Total Revenue of $197.7 Million
01/08/15
Pacira Pharmaceuticals Inc. Announces Changes to EXPAREL® Label
12/12/14
Pacira Pharmaceuticals, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference
11/25/14
Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2014 Global London Healthcare Conference
11/11/14
Pacira Pharmaceuticals Inc. Announces New Data on the Use of EXPAREL to Treat Postsurgical Pain Following Total Knee Arthroplasty
11/06/14
Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue of $50.2 Million and Third Quarter 2014 Results
10/30/14
New Study Correlates Use of EXPAREL for Postsurgical Pain Management with Significant Reductions in Opioid Related Adverse Events
10/27/14
Pacira Pharmaceuticals Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call
10/15/14
Pacira Pharmaceuticals, Inc. Announces Additional Data Supporting Safety of EXPAREL® in Peripheral Nerve Block
10/13/14
Pacira Pharmaceuticals, Inc. Announces Receipt of FDA Warning Letter
09/25/14
Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
08/05/14
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2014 Results: EXPAREL Revenue up 31% Over First Quarter
07/31/14
Pacira Pharmaceuticals Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call
07/17/14
Pacira Pharmaceuticals, Inc. Announces Publication of Pooled Results from IMPROVE Studies Evaluating Health Economic Benefits of EXPAREL®
06/26/14
Pacira Pharmaceuticals, Inc. to Present at June Investor Conferences
05/27/14
Pacira Pharmaceuticals, Inc. Announces sNDA Submission for EXPAREL Nerve Block Indication
05/07/14
Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
05/05/14
Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenue of $34.4 Million and First Quarter 2014 Results
05/01/14
Pacira Pharmaceuticals Announces Timing for First Quarter 2014 Financial Results Webcast and Conference Call
04/17/14
Pacira Pharmaceuticals Announces Grants of Inducement Stock Options Under NASDAQ Listing Rule 5635(c)(4)
04/15/14
Pacira Pharmaceuticals Announces Pricing of Public Offering of Common Stock
04/08/14
Pacira Pharmaceuticals Announces Proposed Public Offering of Common Stock
04/07/14
Pacira Pharmaceuticals Enters into Strategic Co-Production Partnership with Patheon to Create Additional EXPAREL Manufacturing Capacity
04/07/14
EXPAREL Use in Femoral Nerve Block for Total Knee Arthroplasty Further Supported by Additional Data from Phase 3 Pivotal Study, sNDA Submission Planned for Second Quarter 2014
04/04/14
Pacira Pharmaceuticals, Inc. Announces FDA Approval of Additional Manufacturing Suite for EXPAREL
03/31/14
Two New Studies Support Use of EXPAREL for Postsurgical Pain Management Following Total Joint Replacement
03/14/14
Pacira Pharmaceuticals Inc. Appoints Industry Expert Yvonne Greenstreet to its Board of Directors
03/06/14
Pacira Pharmaceuticals Announces EXPAREL® Data Presentations at 2014 Annual Meeting of the American Academy of Orthopedic Surgeons
03/05/14
Pacira Pharmaceuticals, Inc. Announces EXPAREL Phase 3 Clinical Trial in Femoral Nerve Block Meets Primary Efficacy Endpoint
02/27/14
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
02/26/14
Pacira Pharmaceuticals, Inc. Webcast Replay of 2013 Financial Results Conference Call
02/25/14
Pacira Pharmaceuticals, Inc. Reports 2013 Financial Results: Fourth Quarter EXPAREL Revenues Increase 53 Percent Over Third Quarter
02/25/14
Pacira Pharmaceuticals, Inc. Announces Timing for 2013 Financial Results Webcast and Conference Call
02/11/14
Data Update Supports Infiltration with EXPAREL® into the Transversus Abdominis Plane for Postsurgical Pain Management
01/29/14
Phase 4 IMPROVE Publication Finds EXPAREL®- Based Multimodal Analgesia Reduces Opioid Use, Adverse Events and Hospital Stay Following Laparoscopic Surgery
01/07/14
Pacira Pharmaceuticals, Inc. Announces Submission of Prior Approval Supplement for Additional EXPAREL® Manufacturing Suite
12/05/13
Pacira Pharmaceuticals, Inc. to Present at the 25th Annual Piper Jaffray Healthcare Conference
11/25/13
Pacira Pharmaceuticals, Inc. to Present at November Investor Conferences
11/01/13
Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL® Revenue of $20.0 Million and Full Third Quarter 2013 Financial Results
10/31/13
Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
10/17/13
Pacira Pharmaceuticals, Inc. Announces Partnership to Support Uptake of EXPAREL® Among the Orthopedic Marketplace
10/01/13
Study Shows EXPAREL® Provided Improved Pain Control, Shorter Length of Hospital Stay and Substantial Cost Savings Following Total Knee Replacement
09/19/13
Pacira Pharmaceuticals, Inc. Announces Appointment of Life Sciences Industry Veterans Mark Kronenfeld, M.D., and Dennis Winger to its Board of Directors
09/12/13
Pacira Pharmaceuticals, Inc. Reports Second Quarter EXPAREL® Revenue of $15.2 Million and Full Second Quarter 2013 Financial Results
08/06/13
Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2013 Life Sciences Management Access Conference
08/06/13
EXPAREL Phase 3 Clinical Trial in Intercostal Nerve Block Does Not Meet Primary Endpoint
08/01/13
Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
07/30/13
New Study Shows Significant Reduction in Opioids, Length of Hospital Stay and Cost of Care for Patients Receiving EXPAREL® as the Foundation of a Multimodal Postsurgical Pain Regimen
07/18/13
Pacira Pharmaceuticals, Inc. Announces Positive Interim Analysis of EXPAREL in Femoral Nerve Block for Total Knee Arthroplasty
05/29/13
Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2013 Global Healthcare Conference
05/28/13
Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
05/08/13
Pacira Pharmaceuticals, Inc. Reports $10.4 Million in First Quarter EXPAREL Revenue and Full First Quarter 2013 Financial Results
05/08/13
Two New Studies Support Use of EXPAREL via Infiltration Into the Transversus Abdominis Plane for Postsurgical Pain Control
05/06/13
Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
05/01/13
New Published Analysis Finds Opioid-Related Adverse Events Increase Hospital Stays, Costs of Care and Risks of Readmission and Mortality
04/25/13
New Data Support the Benefits of EXPAREL for Postsurgical Analgesia Following Aesthetic Plastic Surgery Procedures
04/12/13
Pacira Pharmaceuticals, Inc. to Close The NASDAQ Stock Market on April 8, 2013
04/05/13
Analysis of Postsurgical Pain Management Finds Opioid-Related Adverse Events Drive Longer Hospital Stays, Greater Cost and Higher Likelihood of Readmission
03/27/13
Pacira Pharmaceuticals, Inc. Reports 2012 Financial Results
03/07/13
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
03/06/13
Pacira Pharmaceuticals, Inc. Announces Timing for 2012 Financial Results Webcast and Conference Call
02/28/13
Pacira Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Health Care Conference
02/25/13
Pacira Pharmaceuticals, Inc. Announces Pricing of $110 Million Private Offering of Convertible Senior Notes
01/17/13
Pacira Pharmaceuticals, Inc. Announces Proposed Offering of $100 Million of Convertible Senior Notes
01/15/13
New Publication Suggests Higher Opioid Use in the Postsurgical Setting May Be Linked to Extended Hospital Stay and Increased Cost of Care
12/18/12
Pacira Pharmaceuticals, Inc. and Aratana Therapeutics Inc. Enter into Global Licensing Agreement for Development and Commercialization of Bupivacaine Liposome Injectable Suspension for Animal Health Indications
12/06/12
New Data Demonstrate Reduction in Opioid Use, Hospital Cost and Length of Stay with EXPAREL as the Foundation of a Multimodal Regimen
11/20/12
Pacira Pharmaceuticals, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
11/20/12
New Data Supporting Use of EXPAREL via Infiltration into the Transversus Abdominis Plane Presented at 11th Annual American Society of Regional Anesthesia and Pain Medicine Meeting
11/13/12
Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
11/08/12
Pacira Pharmaceuticals, Inc. Reports $4.6 Million in Third Quarter EXPAREL® Revenue and Full Third Quarter 2012 Financial Results
11/01/12
Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
10/25/12
Richard A. Baxter, M.D., Receives OR Excellence Award for Use of EXPAREL®
10/18/12
EXPAREL® as the Foundation of a Multimodal Regimen Achieves Statistical Significance in All Primary Endpoints, Including a 60 Percent Reduction in Length of Hospital Stay
10/08/12
Pacira Pharmaceuticals, Inc. Launches EXPAREL® Pivotal Nerve Block Trial
09/25/12
Pacira Pharmaceuticals, Inc. to Present at the UBS Global Life Sciences Conference
09/12/12
Reduced Pain, Opioid Use, and Opioid-Related Adverse Events in Patients Receiving EXPAREL® Compared With Patients Receiving Bupivacaine HCl as a Component of Multimodal Therapy
09/05/12
Pacira Pharmaceuticals, Inc. Reports $2.3 Million in Second Quarter EXPAREL® Revenue and Full Second Quarter 2012 Financial Results
08/09/12
Pacira Pharmaceuticals, Inc. to Present at the Wedbush PacGrow 2012 Life Sciences Management Access Conference
08/07/12
Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2012 Financial Results Webcast and Conference Call
07/31/12
New Data Quantifying the Effects of Opioid Use on Patient Care and Economic Outcomes Presented at Key Medical Meetings
06/05/12
Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
05/29/12
Pacira Pharmaceuticals, Inc. to Be Added to NASDAQ Biotechnology Index
05/21/12
Pacira Pharmaceuticals, Inc. to Present at Bank of America Merrill Lynch 2012 Health Care Conference
05/10/12
Pacira Pharmaceuticals, Inc. Reports First Quarter 2012 Financial Results
05/09/12
Pacira Pharmaceuticals, Inc. Completes $27.5 Million Debt Refinancing
05/03/12
Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2012 Financial Results Webcast and Conference Call
05/02/12
Pacira Pharmaceuticals, Inc. Announces Full Exercise of Overallotment Option by Underwriters
04/25/12
Pacira Pharmaceuticals, Inc. Prices Public Offering of Common Stock
04/12/12
Pacira Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
04/11/12
Pacira Pharmaceuticals, Inc. Announces Commercial Availability of EXPAREL®
04/09/12
Pacira Pharmaceuticals, Inc. Reports 2011 Financial Results
03/27/12
Pacira Pharmaceuticals, Inc. Announces Timing for 2011 Financial Results Webcast and Conference Call
03/20/12
Pacira Pharmaceuticals, Inc. to Present at Barclays Capital Global Healthcare Conference
03/07/12
Pacira Pharmaceuticals, Inc. to Participate in RBC Capital Markets Global Healthcare Conference
02/21/12
Pacira Pharmaceuticals, Inc. Provides Update on Commercial Launch and Product Availability Timing for EXPAREL®
01/09/12
Pacira Pharmaceuticals, Inc. Announces Results from EXPAREL™ Pivotal Trial Published in Diseases of the Colon & Rectum
12/19/11
New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting
12/05/11
Pacira Pharmaceuticals, Inc. Announces Completion of Follow-on Offering of Common Stock and Exercise of Over-Allotment Option
11/22/11
Pacira Pharmaceuticals, Inc. Announces Pricing of Follow-On Offering
11/16/11
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
10/31/11
Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of EXPAREL™ For Postsurgical Pain Management
10/31/11
Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
10/24/11
Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl
10/19/11
Pacira Pharmaceuticals, Inc. Announces Key EXPAREL™ Data to be Presented at American College of Surgeons 97th Annual Clinical Congress
10/18/11
Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
10/11/11
Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL™ Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
09/26/11
Pacira Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference
09/13/11
Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure
09/06/11
Pacira Pharmaceuticals, Inc. to Present at Wedbush Securities 2011 Life Sciences Management Access Conference
08/12/11
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results
08/11/11
Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
08/02/11
Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
07/28/11
Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index
06/27/11
Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months
06/14/11
Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
06/02/11
Pacira Pharmaceuticals, Inc. to Present at UBS Global Specialty Pharmaceuticals Conference
05/24/11
Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting
05/23/11
Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL™ Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
05/16/11
Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
05/11/11
Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
05/05/11
Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
05/04/11
Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
04/08/11
Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
03/31/11
Pacira Pharmaceuticals Announces Timing for 2010 Financial Results, Webcast and Conference Call
03/24/11
Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
03/08/11
Pacira Pharmaceuticals' EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
03/02/11
Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
02/15/11
Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
02/03/11
Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Society’s 57th Annual Meeting
01/13/11
Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
12/14/10
Pacira Announces Results of Another Positive Phase III Trial in Post Operative Pain
12/01/09
Pacira's Phase III Study of EXPAREL™ Meets Primary Pain Relief Endpoint
10/20/09
Phase III Studies of EXPAREL™ (DepoBupivacaine) from Pacira Complete Enrollment
01/06/09
Positive Phase II Study of Pacira’s EXPAREL™ (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
12/14/08
Positive Phase II Study of Pacira's EXPAREL™ (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
12/06/08
Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
10/02/08
Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
08/06/08
Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
07/08/08
Pacira Pharmaceuticals, Inc. Expands Development Collaborations for Depofoam®
04/15/08
Pacira Pharmaceuticals Names David M. Stack CEO and President
12/17/07
Orphan Australia Pty Ltd receives registration approval for the new dose form DepoDur®, Pacira’s modified release injection of morphine sulfate
10/22/07
Flynn Pharma Acquires Rights from Pacira Pharmaceuticals to DepoDur®
09/27/07
EKR Therapeutics Achieves Key Growth Milestone with the Acquisition of Rights from Pacira Pharmaceuticals to DepoDur®
08/15/07
SkyePharma, Inc., Now a Private Pharmaceutical Company, Announces Name Change to Pacira Pharmaceuticals, Inc.
06/22/07